Please login to the form below
opioids
This page shows the latest opioids news and features for those working in and with pharma, biotech and healthcare.
Purdue to pay over $8bn to settle opioid-related criminal claims
The new company will provide opioid overdose reversal medication, as well as addiction treatment medications at no or low cost. ... It will also be permanently bound to injunctive relief, which includes marketing restrictions on the sale and promotion of
Latest news
-
Mallinckrodt files for bankruptcy protection in the US
The bankruptcy filing will reduce Mallinckrodt’s debt by approximately $1.3bn and resolve the opioid-related claims against the company. ... Another opioid drugmaker – Purdue Pharma – filed for bankruptcy last year following increasing blame for
-
Alkermes’ new antipsychotic clears FDA advisory committee hurdle
The committees also jointly voted 11-6 that the labelling is sufficient to mitigate the risks related to the opioid antagonist action of samidorphan. ... Alkermes’ proposed labelling warns against the use of ALKS 3831 in patients who are
-
US states claim Purdue Pharma owes $2.2 trillion over opioid crisis
Last year, Purdue filed for bankruptcy following increasing blame for its part in driving the opioid epidemic in the US. ... well as millions of doses of lifesaving opioid addiction treatment and overdose reversal medicines,” Purdue said in a statement.
-
Q&A: Kate Paxton
opioid crisis was also incredibly rewarding.
-
Trevena gets second go at FDA approval for pain drug
The FDA has set a date of 7 August to complete its review of the marketing application for the intravenously-administered drug, a mu-opioid receptor agonist which is billed as ... the risk of respiratory and gastrointestinal side effects seen with other
More from news
Approximately 35 fully matching, plus 149 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
Hahn is taking over as the FDA is being thrust into the spotlight on a number of issues, including how to deal with medicine prices, the opioid epidemic, hastening access to
-
20 for 2020 – Five pharma companies to watch
year. We’re talking about the lawsuits J&J is facing claiming damages as a result of using its products, including opioid painkillers, Baby Powder talc and its schizophrenia drug Risperdal ... epidemic in opioid abuse and overdose-related deaths in the
-
Will biosimilars ever catch on in the US?
First-to-market generics included medicines for opioid overdose, pulmonary arterial hypertension, breast cancer, seizures, depression and various infections.
-
The transatlantic opioid crisis
There’s some evidence to suggest similar transgressions in the UK with opioids. ... In another case, a single GP had ten patients addicted to synthetic opioids.
-
As the opioid crisis grabs the headlines, the search for safe treatments continues
European operations, said the company is close to new registrations in Europe for opioid addiction products. ... be fully dedicated to helping patients, doctors and communities dealing with opioid addiction.’.
More from intelligence
Approximately 2 fully matching, plus 25 partially matching documents found.
Latest appointments
-
New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals
DeVarney joined Titan over ten years ago, and has lead the development of its opioid addiction treatment Probuphine.
-
Egalet appoints Stan Musial as CFO
s pipeline of abuse-deterrent opioids are nearing phase III.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD) conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018. ... The two-day event succeeded in delivering what IOTOD is well known for: expert
-
IOTOD: Improving Opioid Dependence Outcomes
IOTOD’s future. The IOTOD educational initiative perpetually aims to provide the most up-to-date information in the field of opioid addiction. ... in opioid addiction and gain valuable insight on some of the most controversial topics in the field.
-
"Legal highs" ruling leaves illegal labs laughing
So we are acutely aware of the devastation caused by the opioid epidemic in the US, and the criticism aimed at Purdue, the maker of OxyContin. . ... We have also pitched for agents designed to treat opioid overdose and alcohol abuse. .
-
Research Partnership has published a new Living with Chronic Pain market report for 2016
At least 60% of the patients surveyed are currently prescribed long acting opioids (LAOs).
-
How digital content is helping physicians curb the opioid abuse epidemic
using their state’s Prescription Drug Monitoring Program (PDMP) database before prescribing opioids to a patient. ... topic. And there’s plenty of evidence that this approach works—having a measurable and almost immediate impact on how physicians
More from PMHub
Approximately 1 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
-
Account Management
-
Competitive Salary Offered
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Content Editor - Biotechnology
-
Salary TBC
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- GSK discontinues two feladilimab trials in head and neck cancer
- AZ showcases data for next-generation PARP inhibitor AZD5305
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- Pfizer/BioNTech say their COVID-19 vaccine can be stored at warmer temperatures
- Oxford study finds standard asthma medication improves recovery time in COVID-19 patients
- Live Webinar: Advancing Human Health Through Precise Measures of Movement, Cognition & Biometrics
- Live Webinar: How to Simplify Genetics & Raise Awareness Around Orphan Diseases
- Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Alexion and NICE agree confidential discount for Ultomiris use on the NHS
- Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
PMHub
Kendle Healthcare
Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...
Latest intelligence
- InSite Events™ National Pharma Meeting: A Customer Story
- How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
- Fear or encouragement, which is best to drive behaviour change?
- The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
- The unheard, unseen, and uncorrected effects of COVID-19
- The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...
Quick links
Infographics
